Rachel Hill, MD
Dermatology · Daniel Island, SCNPI 1336377738
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,910 of the $5,807 with a category attached, or 84.5%. Senseonics, Incorporated accounts for 78.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $3,453 and has fallen 96.2% since, to $131 in 2025.
Across 42 payments — averaging $138.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Senseonics, Incorporated$5K
- Biofrontera Inc.$503
- AbbVie$320
- Novartis$115
- Verrica Pharmaceuticals Inc.$80
- Ascensia Diabetes Care US Inc.$77
- plus $151 from 5 others
What the payments were for
- Speaking & faculty fees$4,91085%
- Food & beverage$88215%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Senseonics, Incorporated | 9 | $4,560 |
| Biofrontera Inc. | 6 | $503 |
| AbbVie(2 entities) | 7 | $320 |
| Novartis | 4 | $115 |
| Verrica Pharmaceuticals Inc. | 4 | $80 |
| Ascensia Diabetes Care US Inc. | 4 | $77 |
| Galderma Laboratories, L.p. | 3 | $51 |
| Incyte Corporation | 2 | $38 |
| Amgen | 1 | $26 |
| Johnson & Johnson | 1 | $21 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Eversense$4,560
- AMELUZ$350
- BF-RhodoLED$350
- XEPI$350
How this compares
$5,807 in reported general payments places this provider in the 65th percentile of 203 dermatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 13 | $53,450 |
| Tretinoin | 27 | $1,671 |
| Fluorouracil | 21 | $1,499 |
| Clobetasol Propionate | 32 | $908 |
| Ketoconazole | 34 | $444 |
| Triamcinolone Acetonide | 31 | $190 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Daniel Island
- Marshall ShulerGreenville$2.6M
- Rebecca SmithFort Mill$2.3M
- Todd SchlesingerCharleston$1.9M
- Amylynne FrankelSpartanburg$987K
- Marguerite GermainMt Pleasant$200K
- George KeoughPawleys Island$150K
- Christopher MartinAbbeville$129K
- Lee CarsonGreenville$127K
- Mark SiegelCharleston$120K
- Jeffrey SmithWest Columbia$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.